Are you Dr. Pegram?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 64 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
900 Blake Wilbur Dr
First floor
Palo Alto, CA 94304Phone+1 650-498-6004Fax+1 650-736-0607- Is this information wrong?
Summary
- Dr. Mark Pegram, MD is an oncologist in Palo Alto, California. He is currently licensed to practice medicine in California, Florida, and Texas. He is affiliated with Stanford Health Care and is a Professor at Stanford University Sch of Med.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1986 - 1989
- University of North Carolina at Chapel Hill School of MedicineClass of 1986
Certifications & Licensure
- CA State Medical License 1989 - 2024
- FL State Medical License 2008 - 2012
- TX State Medical License 1989 - 1990
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2007, 2010-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 2001 Dec 01
- Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2003 May 01
- GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.Tara B Sanft, Jenna Wong, Brandon O'Neal, Natalia Siuliukina, Rachel C Jankowitz, Mark D Pegram, Jenny R Fox, Yi Zhang, Kai Treuner, Joyce A O'Shaughnessy> ;Journal of the National Comprehensive Cancer Network. 2024 Mar 4
- Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark Pegram> ;NPJ Breast Cancer. 2023 Nov 17
- 8 citationsEstrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.Mark Pegram, Christian Jackisch, Stephen R D Johnston> ;NPJ Breast Cancer. 2023 May 31
- Join now to see all
Press Mentions
- Meet 7 Femtech Companies Innovating in the Area of Ovarian Health, Breast and Gynecological CancersMarch 16th, 2022
- Clinical Picture Brightens for HER2+ Breast Cancer with Brain MetastasesMarch 7th, 2022
- Cedars-Sinai, Rubedo Partner to Develop Targeted IPF TreatmentsJune 8th, 2021
- Join now to see all
Hospital Affiliations
- Stanford Health CarePalo Alto, California